바카라 게임 BG Rhee: “Strengthening Asian cooperation is necessary in the global new drug development trend”
[by Ji, Yong Jun] The Korea National Enterprise for Clinical Trials (KONECT) announced on March 5 that BG Rhee, CEO of GI Innovation, has been appointed as the program committee 바카라 게임 for the 2025 KoNECT-MOHW-MFDS International Conference (KIC).
The program committee 바카라 게임 is tasked with overseeing the overall structure of the program committee for the 2025 KIC, as well as planning and managing the conference. The upcoming event aims to deliver a comprehensive and practical agenda, with approximately 30 committee members contributing under the theme of ‘Transforming Clinical Trials Through Technology, Diversity, and Collaboration.’
During the program committee 바카라 게임 appointment meeting on February 11, CEO BG Rhee said, “Strengthening cooperation in Asia is important for Korean companies to achieve global competitiveness in the pharmaceutical and biotech ecosystem centered on the U.S. and Europe.” He added, “Asia should seek joint growth through a consultative body such as ‘Bio Asia,’ similar to major biotechnology events of the U.S. and Europe.”
Now in its 11th year, the 2025 KIC will take place at the Lotte Hotel Seoul over three days, from September 22. As the largest 바카라 게임 trial conference in Asia, it is expected to attract approximately 1,500 participants from both Korea and overseas, including pharmaceutical and biotech company representatives, 바카라 게임 researchers, regulatory authorities, and 바카라 게임 trial contract organizations.
“The 2025 KIC is expected to establish itself as a platform for cooperation and growth in the Asian pharmaceutical and biotech industry, highlighting the extensive experience and expertise accumulated by Program Committee 바카라 게임 BG Rhee in his roles as CEO of GC Biopharma, 바카라 게임 of the Korea Biotechnology Industry Organization (KoreaBio), and President of the Council for Advanced Regenerative Medicine (CARM),” stated Park In-seok, President of the Korea National Enterprise for Clinical Trials (KONECT).